Synthetic Biologics Inc. (AMEX: SYN) is 128.49% higher on its value in year-to-date trading and has touched a low of $0.25 and a high of $1.70 in the current 52-week trading range. The SYN stock was last observed hovering at around $0.65 in the last trading session, with the day’s gains setting it 0.23% off its average median price target of $1.38 for the next 12 months. It is also 41.33% off the consensus price target high of $1.50 offered by 1 analysts, but current levels are 29.6% higher than the price target low of $1.25 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $0.88, the stock is 87.97% and 119.81% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 46.7 million and changing 33.75% at the moment leaves the stock 103.90% off its SMA200. SYN registered 76.75% gain for a year compared to 6-month loss of 78.41%. The firm has a 50-day simple moving average (SMA 50) of $0.4455 and a 200-day simple moving average (SMA200) of $0.4580.
The stock witnessed a 130.29% gain in the last 1 month and extending the period to 3 months gives it a 179.23%, and is -12.49% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 25.66% over the week and 18.05% over the month.
Distance from 52-week low is 246.99% and -48.52% from its 52-week high.
Synthetic Biologics Inc. (SYN) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Synthetic Biologics Inc. (SYN) is a “Hold”. 1 analysts offering their recommendations for the stock have an average rating of 2.50, where 1 rate it as a Hold and 0 think it is a “Overweight”. 0 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Synthetic Biologics Inc. is expected to release its quarterly report on 05/11/2021 and quarterly earnings per share for the current quarter are estimated at -$0.13.The EPS is expected to grow by 75.90% this year.
Synthetic Biologics Inc. (SYN) Top Institutional Holders
28 institutions hold shares in Synthetic Biologics Inc. (SYN), with 74.17k shares held by insiders accounting for 0.37% while institutional investors hold 7.15% of the company’s shares. The shares outstanding are 19.99M, and float is at 19.92M with Short Float at 1.04%. Institutions hold 7.12% of the Float.
The top institutional shareholder in the company is Renaissance Technologies, LLC with over 0.86 million shares valued at $0.41 million. The investor’s holdings represent 4.30% of the SYN Shares outstanding. As of Sep 29, 2020, the second largest holder is Vanguard Group, Inc. (The) with 0.12 million shares valued at $58575.0 to account for 0.62% of the shares outstanding. The other top investors are Bridgeway Capital Management, Inc. which holds 0.11 million shares representing 0.55% and valued at over $51884.0, while Acadian Asset Management holds 0.36% of the shares totaling 72789.0 with a market value of $34552.0.
Synthetic Biologics Inc. (SYN) Insider Activity
A total of 0 insider transactions have happened at Synthetic Biologics Inc. (SYN) in the last six months, with sales accounting for 0 and purchases happening 0 times.